Oncotarget

Research Papers:

Urokinase-type plasminogen activator receptor promotes proliferation and invasion with reduced cisplatin sensitivity in malignant mesothelioma

Shenqi Wang, Li Jiang, Yipeng Han, Shan Hwu Chew, Yuuki Ohara, Shinya Akatsuka, Liang Weng, Koji Kawaguchi, Takayuki Fukui, Yoshitaka Sekido, Kohei Yokoi and Shinya Toyokuni _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:69565-69578. https://doi.org/10.18632/oncotarget.11829

Metrics: PDF 853 views  |   HTML 2140 views  |   ?  


Abstract

Shenqi Wang1, Li Jiang1, Yipeng Han2, Shan Hwu Chew1, Yuuki Ohara1, Shinya Akatsuka1, Liang Weng2, Koji Kawaguchi3, Takayuki Fukui3, Yoshitaka Sekido4,5, Kohei Yokoi3, Shinya Toyokuni1

1Department of Pathology and Biological Responses, Nagoya University Graduate School of Medicine, Nagoya, 466–8550, Japan

2Department of Tumor Pathology, Nagoya University Graduate School of Medicine, Nagoya, 466–8550, Japan

3Department of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya, 466–8550, Japan

4Department of Cancer Genetics, Nagoya University Graduate School of Medicine, Nagoya, 466–8550, Japan

5Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, 464–8681, Japan

Correspondence to:

Shinya Toyokuni, email: toyokuni@med.nagoya-u.ac.jp

Keywords: malignant mesothelioma, uPAR, cisplatin, AKT signaling pathway

Received: May 12, 2016     Accepted: August 25, 2016     Published: September 02, 2016

ABSTRACT

Malignant mesothelioma (MM) is a rare neoplasm associated with asbestos exposure. The prognosis of MM is poor because it is aggressive and highly resistant to chemotherapy. Using a rat model of asbestos-induced MM, we found elevated urokinase-type plasminogen activator receptor (uPAR; Plaur) expression in rat tissues, which was associated with poor prognosis. The proliferation, migration and invasion of MM cells were suppressed by uPAR knockdown and increased by overexpression experiments, irrespective of urokinase-type plasminogen activator (uPA; Plau) levels. More importantly, we found that uPAR expression is associated with sensitivity to cisplatin in MM through the PI3K/AKT pathway, which was demonstrated with specific inhibitors, LY294002 and Akti-1/2. uPAR knockdown significantly increased sensitivity to cisplatin whereas its overexpression significantly decreased cisplatin sensitivity. Furthermore, sera and tissues from MM patients showed significantly high uPAR levels, which suggested the pathogenic role of uPAR in the tumor biology of human MM. In conclusion, our findings indicate that uPAR levels are associated with malignant characteristics and cisplatin sensitivity of MM. In addition to the potential use of uPAR as a prognostic marker, the combination of uPAR abrogation and cisplatin may reveal a promising therapeutic approach for MM.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 11829